G6PD deficiency in Latin America: systematic review on prevalence and variants

Memórias do Instituto Oswaldo Cruz

Wuelton M Monteiro¹  Fernando Fa Val¹  André M Siqueira¹  Gabriel P Franca¹  Vanderson S Sampaio¹  Gisely C Melo¹  Anne Cg Almeida¹  Marcelo Am Brito¹  Henry M Peixoto¹  Douglas Fuller¹  Quique Bassat¹  Gustavo As Romero¹  Oliveira Maria Regina F¹  Lacerda Marcus Vinícius G¹ 

关键词: G6PD deficiency;    malaria control;    Plasmodium vivax;    primaquine;    haemolysis;    Amerindians;   

DOI  :  10.1590/0074-0276140123

来源: SciELO

【 摘 要 】

Plasmodium vivax radical cure requires the use of primaquine (PQ), a drug that induces haemolysis in glucose-6-phosphate dehydrogenase deficient (G6PDd) individuals, which further hampers malaria control efforts. The aim of this work was to study the G6PDd prevalence and variants in Latin America (LA) and the Caribbean region. A systematic search of the published literature was undertaken in August 2013. Bibliographies of manuscripts were also searched and additional references were identified. Low prevalence rates of G6PDd were documented in Argentina, Bolivia, Mexico, Peru and Uruguay, but studies from Curaçao, Ecuador, Jamaica, Saint Lucia, Suriname and Trinidad, as well as some surveys carried out in areas of Brazil, Colombia and Cuba, have shown a high prevalence (> 10%) of G6PDd. The G6PD A-202A mutation was the variant most broadly distributed across LA and was identified in 81.1% of the deficient individuals surveyed. G6PDd is a frequent phenomenon in LA, although certain Amerindian populations may not be affected, suggesting that PQ could be safely used in these specific populations. Population-wide use of PQ as part of malaria elimination strategies in LA cannot be supported unless a rapid, accurate and field-deployable G6PDd diagnostic test is made available.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License